Scientific Evidence

Real-world evidence confirms risk stratification of the 31-GEP and i31-GEP in prospectively tested patients with stage I-III cutaneous melanoma

Jan 2024

Author: Pariser D, et al.

Publication: Poster, presented at the 2024 Winter Clinical Dermatology Conference - Hawaii®, Honolulu, Hawaii, January 12-17, 2024

Diagnostic utility of the 23-gene expression profile test for an atypical intradermal melanocytic proliferation

Dec 2023

A case report describing how MyPath GEP testing leads to diagnostic clarity in a histopathologically ambiguous melanocytic lesion on the face of a 34-year-old man.

Author: Marks E, et al.

Publication: Future Medicine

A physician’s guide to the use of gene expression profile ancillary diagnostic testing for cutaneous melanocytic neoplasms

Dec 2023

Author: Marks E, et al.

Publication: Journal of Clinical and Aesthetic Dermatology

A Physician’s Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms

Dec 2023

A real-world assessment of common use scenarios of MyPath GEP testing by dermatopathologists and dermatologists to achieve definitive diagnoses and personalized patient management plans.

Author: Marks E, et al.

Publication: Journal of Clinical and Aesthetic Dermatology

Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi-center performance cohort of cutaneous melanocytic neoplasms

Nov 2023

Accuracy data in an independent, multi-center cohort of 2512 melanocytic lesions

Author: Goldberg M, et al.

Publication: Skin

IDgenetix-Guided Medication Management for Major Depressive Disorder: Confirmation of Randomized Controlled Trial Outcomes by Real-World Evidence

Nov 2023

This study compared the clinical outcome results from Bradley et al. (2018) with real-world evidence. Patient response and remission rates strongly aligned between both studies.

Author: Cao F, Hanson A, Cook R

Publication: Poster at NEI Congress 2023

A Tissue Systems Pathology Test Outperforms the Standard of Care Variables in Predicting Progression in Patients with Barrett’s Esophagus

Nov 2023

This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.

Author: Davison JM, et al.

Publication: Clinical and Translational Gastroenterology

An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients with Barrett's Esophagus

Nov 2023

Management guided by the TissueCypher test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.

Author: Duits, Lucas C, et al.

Publication: American Journal of Gastroenterology

The Tissue Systems Pathology Test Outperforms Pathology Review in Risk-Stratifying Patients with Low-Grade Dysplasia

Nov 2023

This study aimed to compare the risk stratification performance of the TissueCypher test vs benchmarks of generalist and expert pathology.

Author: Khoshiwal AM, et al.

Publication: Gastroenterology

A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients with Barrett’s Esophagus

Nov 2023

This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.

Author: Davison JM, et al.

Publication: Clinical and Translational Gastroenterology

Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi center performance cohort of cutaneous melanocytic neoplasms

Oct 2023

Author: Goldberg M, et al.

Publication: Poster, presented at the 2023 ASDP Annual Meeting

The tissue systems pathology test predicts risk of progression in Medicare-eligible patients with Barrett’s esophagus

Oct 2023

TissueCypher risk-stratifies BE patients ≥ 65 years old independently of clinicopathologic variables and has significantly higher sensitivity for detection of progressors than pathology diagnosis of LGD. 

Author: Khara HS, et al.

Publication: Poster presentation (S599) at ACG 2023, Vancouver